{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-139366","form_type":"8-K","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.727556+00:00","generated_at":"2026-06-01T23:22:01.434501+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Mereo BioPharma Q1 net loss $9.0M, cash $48.7M; setrusumab enrollment complete","bullets":["Net loss $9.0M in Q1 2024 vs $12.1M in Q1 2023; operating loss $9.9M.","Cash and equivalents $48.7M as of March 31, 2024, down from $57.4M at Dec 31, 2023.","Phase 3 Orbit study (setrusumab) fully enrolled (158 patients); Cosmic enrolled 69 patients.","Alvelestat SGRQ validation completed; Phase 3 protocol to be submitted to FDA in H1 2024.","Cash guidance unchanged: funds operations into 2026; no alvelestat partnership upfront included."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-139366","json":"https://secwatch.observer/filing/0001193125-24-139366.json","markdown":"https://secwatch.observer/filing/0001193125-24-139366.md","text":"https://secwatch.observer/filing/0001193125-24-139366.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524139366/0001193125-24-139366-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524139366/d787110d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:22:01.434501+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}